← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Signablok, Inc.
Worcester, MA
$7,631,927
Total funding
16
Grants
Funding over time
peak $1.7M · FY2012–25$2M$1.5M$1M$500K$0
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$7,631,927 · 16
By mechanism
R44$4,707,839 · 4
R43$2,768,231 · 11
R21$155,857 · 1
Investigators at Signablok, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Largest grants
First-in-class TREM-1 inhibitors in combination therapy for pancreatic cancer$1,198,246
R44 · FY2020 · CA
First-in-class TREM-1 inhibitors for neovascular retinal diseases$830,491
R44 · FY2025 · EY
First-in-class TREM-1 inhibitors in combination therapy for pancreatic cancer$799,560
R44 · FY2019 · CA
Multifunctional nanoformulations for diagnostic imaging of atherosclerosis$673,165
R44 · FY2015 · HL
Multifunctional nanoformulations for diagnostic imaging of atherosclerosis$669,647
R44 · FY2014 · HL
TREM-1 therapy for the treatment of empyema$457,954
R43 · FY2025 · HL
First-in-class TREM-1 inhibitors for neovascular retinal diseases$278,127
R44 · FY2023 · EY
New mechanism-based TREM-1 therapy for acute respiratory distress syndrome$272,741
R43 · FY2023 · HL
TREM-1 therapy for rheumatoid arthritis$258,603
R44 · FY2020 · AR
TREM-1 inhibitor for the treatment of scleroderma$249,601
R43 · FY2020 · AR
Development of first-in-class TREM-1 inhibitors for neovascular retinal diseases$226,223
R43 · FY2018 · EY
Novel TREM-1 targeting therapies for sepsis$224,996
R43 · FY2018 · GM
First-in-class TREM-1 inhibitors in combination therapy for pancreatic cancer$224,672
R43 · FY2017 · CA
Treatment of alcoholic liver disease with novel targeted inhibitors$223,443
R43 · FY2016 · AA
Novel mechanism-based targeted approach to rheumatoid arthritis$223,013
R43 · FY2014 · AR
Multifunctional nanoformulations for diagnostic imaging of atherosclerosis$221,829
R43 · FY2012 · HL
Development of novel targeted agents in lung cancer$221,738
R43 · FY2012 · CA
Development of novel targeted agents in pancreatic cancer$219,937
R43 · FY2015 · CA
Novel medical countermeasure to mitigate potentially lethal acute radiation syndrome$155,857
R21 · FY2025 · AI
First-in-class TREM-1 inhibitors in combination therapy for pancreatic cancer$2,084
R43 · FY2019 · CA